Pfizer (PFE) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
May 5, 2026 6:45 AM EDTEarnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts Robust LateStage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2).
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
We're off to a strong start in... More
